Safety of abatacept or infliximab in RA patients with an inadequate response to MTX: Results from a 1-year double-blind randomized clinical trial

Category Primary study
JournalScandinavian journal of rheumatology
Year 2008
This article has no abstract
Epistemonikos ID: 7d0a9449604cf9c980b7c442a6fffbfa71f04018
First added on: Oct 21, 2017